ArticleNature communications2020
Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 103 citations in OpenAlex.
- Construction and Immunogenicity of Modified Vaccinia Ankara (MVA) Viruses Expressing E1 and E2 Proteins of Bovine Viral Diarrhea Virus.Vaccines · 2026Article
- Vaccine-derived T-cell responses are insufficient to generate protective immunity to SARS-CoV-2.Scientific reports · 2026Article
- Genomic assembly, rescue, and characterization of a functional pseudorabies virus.Virologica Sinica · 2026Article
- SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platform.Nature communications · 2025Article
- Design and construction of a fast synthetic modified vaccinia virus Ankara reverse genetics system for advancing vaccine development.Frontiers in microbiology · 2025Article
- Selective Deletion of HLA-B, and -C Class I Genes Promotes Immunocompatibility of Humanized Skin Graft Model.ImmunoTargets and therapy · 2025Article
- Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.Frontiers in immunology · 2025Article
- Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.Emerging microbes & infections · 2024Article
- Article
- Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study.International journal of molecular sciences · 2024Article
- Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.Journal of virology · 2024Article
- Vaccine approaches and treatment aspects against Crimean Congo hemorrhagic fever.Virusdisease · 2024Review
- Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2.Vaccines · 2024Article
- Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.Biomolecules · 2024Review
- Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform.NPJ vaccines · 2024Article
- Article
- Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus.Communications medicine · 2024Article
- Review
- The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein.Journal of immunology research · 2024Review
- A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.Molecular therapy. Methods & clinical development · 2023Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
- Update of
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
Abstract
Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.